Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2014-07-31 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a joint announcement by GlaxoSmithKline (GSK) and Genmab A/S dated July 31, 2014, reporting the positive interim analysis results of their Phase III PROLONG study for the drug ofatumumab. It details clinical findings (met primary endpoint for efficacy) and discusses future plans to share data with regulatory agencies to evaluate potential future regulatory filings. This content is a high-level summary of clinical trial progress and results, typical of an announcement intended for investors and the public regarding ongoing development, rather than a full financial report (10-K, IR) or a formal earnings release (ER). Since it is a specific announcement about clinical trial progress and future regulatory steps, it best fits the category for general regulatory/company announcements that aren't strictly financial or management changes. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-financial, non-management corporate updates that don't fit a more specific clinical/product category (which we lack). However, because it is a detailed announcement of a major clinical milestone and its implications for future regulatory action, it is a significant corporate event announcement. Since there is no specific 'Clinical Trial Update' category, and it is not a formal Earnings Release (ER) or Interim Report (IR) which focus on financial performance, RNS is the most appropriate fallback for a significant, non-standard filing. It is not a 'Report Publication Announcement' (RPA) because it is the content itself, not just an announcement that a report is available.
2014-07-31 English
Earnings Release 2014
Earnings Release Classification · 100% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and is very short (4155 characters). It provides key financial highlights for the second quarter of 2014 regarding a specific product (Arzerra/ofatumumab) and the expected royalty payment. This format—a brief, immediate release of key periodic financial figures—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a general regulatory filing (RNS), as it fits the specific definition of an initial announcement of periodical financial results. Q2 2014
2014-07-23 Danish
Earnings Release 2014
Earnings Release Classification · 98% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and provides key financial highlights for the second quarter of 2014 regarding the net revenue of Arzerra®. It explicitly states the revenue figures and the expected royalty payment. This format, focusing on immediate, summarized financial results for a specific period (Q2 2014), aligns perfectly with the definition of an Earnings Release (ER), which covers initial announcements of periodical financial results (key highlights only). It is too brief and summary-focused to be a full Interim Report (IR) or Annual Report (10-K). Q2 2014
2014-07-23 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and is dated July 18, 2014. It details an operational update regarding a planned Phase III clinical trial (MMY3007) for the drug daratumumab, including study design, endpoints, and collaboration details with Janssen. This type of announcement, focusing on clinical development progress, partnership updates, and forward-looking statements about drug trials, is characteristic of corporate communications in the biotech/pharma sector. It is not a formal financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). Since it is a specific operational/pipeline update that doesn't fit the other specialized categories (like DIRS, DIV, CAP), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a formal disclosure to the market about a material event. Given the specific nature of the content (clinical trial update), it is a material event disclosure, fitting the broad 'Regulatory Filings' category when a more specific category like 'LTR' (Legal Proceedings) or 'ER' (Earnings) does not apply.
2014-07-18 Danish
Legal Proceedings Report 2014
Legal Proceedings Report Classification · 99% confidence The document is titled "Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma" and is explicitly labeled as a "Company Announcement." It details plans for a clinical trial (MMY3007), provides updates on product development (daratumumab), and includes standard forward-looking statements and contact information typical of corporate news releases regarding operational or clinical progress. This content does not fit the definitions for a formal financial report (10-K, IR, ER, MRQ), a governance document (CGR, DEF 14A), or a shareholder vote result (DVA). Since it is a general announcement about business operations and clinical development, it is best classified as a Regulatory Filing (RNS) as a general corporate announcement, or potentially an Investor Presentation (IP) if it were a slide deck, but given the format, RNS serves as the most appropriate general regulatory/corporate news category when specific operational/clinical updates are the focus and it's not a formal financial filing.
2014-07-18 English
M&A Activity 2014
M&A Activity Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details a specific business event: receiving a milestone payment from Janssen related to the DuoBody platform. It includes financial updates (USD 3 million payment) and strategic partnership details. This type of announcement, which is a formal communication to the market about a significant, non-periodic business development (like a partnership milestone or legal event), typically falls under general regulatory announcements or specific event disclosures. Since it is not a full Annual Report (10-K), Quarterly Report (IR), Earnings Release (ER), or a specific filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate general category for a formal, non-standard regulatory disclosure in Danish is 'Regulatory Filings' (RNS), which serves as a broad category for company announcements not covered elsewhere. It is not a short announcement pointing to a larger report, so RPA is less likely than RNS for the content itself.
2014-07-14 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.